The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation
Open Access
- 7 May 2021
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (2), 294-302
- https://doi.org/10.20996/1819-6446-2021-04-17
Abstract
Anticoagulant therapy of patients with atrial fibrillation is an integral part of their treatment strategy. The high risk of developing a cardioembolic stroke and the high comorbidity of this group of patients necessitates a comprehensive approach to treatment, taking into account all available risk factors. Atrial fibrillation is often asymptomatic and timely detection of these patients can be one of the most important tasks in the complex of measures aimed at protecting patients from stroke. The European Society of Cardiology's 2020 guidelines suggest the use of a CC to ABC patient management strategy. This strategy involves a number of measures aimed at managing atrial fibrillation, including confirming the diagnosis, determining the characteristics of atrial fibrillation and treatment tactics. One of the points of this strategy is the control of comorbidities and risk factors for cardiovascular diseases. To date, rivaroxaban has a number of convincing and reliable data on a high profile of efficacy and safety in the treatment of comorbid patients who not only have a high risk of stroke, but also need protection from coronary events and decreased renal filtration function. These data are confirmed by both the results of randomized clinical trials and data from real clinical practice. The review discusses the literature data describing the condition of patients with atrial fibrillation while taking direct oral anticoagulants, according to the search query “Atrial fibrillation, effectiveness and safety of rivaroxaban, warfarin, comorbidity, atrial fibrillation, efficacy and safety of rivaroxaban, warfarin, comorbid status” for the period from 2010 to 2020 in open sources PubMed and e-library, and a strategy for the comprehensive protection of patients with atrial fibrillation when using rivaroxaban is proposed for consideration.Keywords
This publication has 73 references indexed in Scilit:
- Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF ConsortiumJournal of the American Heart Association, 2013
- Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trialsBMJ Open, 2012
- Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studiesCMAJ : Canadian Medical Association Journal, 2012
- Relation of Renal Function to Risk for Incident Atrial Fibrillation in WomenThe American Journal of Cardiology, 2012
- Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rateKidney International, 2011
- Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacksEmergencias, 2007
- Silent Brain Infarcts and the Risk of Dementia and Cognitive DeclineThe New England Journal of Medicine, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- The hemodynamic consequences of cardiac arrhythmias: Evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine modelAmerican Heart Journal, 1983